RetinalGenix Technologies Inc. Files Q2 2024 10-Q

TL;DR

RTGN 10-Q filed for Q2 2024. Check financials.

AI Summary

RetinalGenix Technologies Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, operates in the Surgical & Medical Instruments & Apparatus sector. Its principal business address is in Petaluma, California. The filing covers the second quarter of 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for RetinalGenix Technologies Inc. during the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine quarterly filing and does not inherently indicate new risks.

Key Numbers

• Q2 2024 — Reporting Period (Financial reporting for the second quarter of 2024.)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• RetinalGenix Technologies Inc. (company) — Filer
• Petaluma, California (location) — Business Address
• 20240630 (date) — Period of Report
• 20240819 (date) — Filing Date

FAQ

Key Financial Figures

• $0.01 — F Original Issue Price" initially means $0.01 and "Series F Conversion Pric

Filing Documents

• form10-q.htm (10-Q) — 748KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-24-033012.txt ( ) — 3623KB
• rtgn-20240630.xsd (EX-101.SCH) — 25KB
• rtgn-20240630_cal.xml (EX-101.CAL) — 27KB
• rtgn-20240630_def.xml (EX-101.DEF) — 128KB
• rtgn-20240630_lab.xml (EX-101.LAB) — 231KB
• rtgn-20240630_pre.xml (EX-101.PRE) — 193KB
• form10-q_htm.xml (XML) — 456KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3936890 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1450 North McDowell Boulevard , Suite 150 Petaluma , CA 94954 (Address of principal executive offices) (Zip Code) (415) 578-9583 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Act: None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The number of shares of the issuer's common stock, $ 0.0001 par value per share, outstanding at August 16, 2024 was 17,996,033 . PART I — FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED BALANCE SHEETS June 30, 2024 (unaudited) December 31, 2023 ASSETS Current Assets Cash $ 86,913 $ 0 Total Current Assets 86,913 0 Equipment, net of accumulated depreciation of $ 201 and $ 151 at June 30, 2024 and December 31, 2023, respectively 106 156 TOTAL ASSETS $ 87,019 $ 156 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Liabilities Accounts payable and accrued liabilities 862,453 884,920 Due to Sanovas 430,309 2,760 Due to related parties 543,061 457,534 Shareholders' notes payable 49,000 49,000 Accrued interest payable 13,519 11,599 Total Liabilities 1,898,342 1,405,813 Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at June 30, 2024 and December 31, 2023 - - Common stock, $ 0.0001 par value; 80,000,000 shares authorized; 17,924,922 and 17,635,478 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1,792 1,819 Additional paid in capital 12,105,589 9,701,719 Accumulated deficit ( 13,918,704 ) ( 11,109,195 ) Total Stockholders' Deficit ( 1,811,323 ) ( 1,405,657 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 87,019 $ 156 The accompanying notes are an integral part of these consolidated financial statements. 2 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED For The Three Months Ended June 30, 2024 2023 Revenues $ - $ - Operating expenses: General and administrative expenses 368,738 120,097 Research and development 82,926 152,577 Stock-based compensation 211,009 78,509 Total operating expenses 662,673 351,183 Interest expense 960 960 Net loss $ ( 663,633 ) $ ( 352,143 ) Net loss per share - basic and diluted $ ( 0.04 ) $ ( 0.02 ) Weighted average number of common shares outstanding during the period- basic and diluted 17,863,564 17,272,116 The accompanying notes are an integral part of these consolidated financial statements. 3 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED For The Six Months Ended June 30, 2024 2023 Revenues $ - $ - Operating expenses: General and administrative expenses 697,723 323,339 Re

View Full Filing

View this 10-Q filing on SEC EDGAR